meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunosuppressants drugs
abatacept
adalimumab
anakinra
anti-interleukin-6
clazakizumab
Levilimab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
canakinumab
cenicriviroc
complement inhibitors
CRAC-channel inhibitors (auxora)
eculizumab
emapalumab
fostamatinib
infliximab
itolizumab
ixekizumab
jakotinib
janus kinase (JAK) inhibitor
lenzilumab
pamrevlumab
tacrolimus
tetrandrine
thalidomide
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
corticosteroids
dexamethasone
Immunosuppressants drugs
anti-interleukin-6
tocilizumab
antiviral and associated therapy
favipiravir
control
placebo
standard of care
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
corticosteroids: no
corticosteroids: yes
critical disease
severe disease
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded